Statin for the Primary Prevention of Cardiovascular Disease in Patients with Diabetes Mellitus

Bo Kyung Koo

doi:10.4093/dmj.2014.38.1.32

Articles

Page Path: HOME > Diabetes Metab J > Volume 38(1); 2014 > Article

Editorial Clinical Care/Education Statin for the Primary Prevention of Cardiovascular Disease in Patients with Diabetes Mellitus: Bo Kyung Koo^1,2; Diabetes & Metabolism Journal 2014;38(1):32-34.
DOI: https://doi.org/10.4093/dmj.2014.38.1.32
Published online: February 19, 2014

3,287 Views
34 Download
14 Web of Science
15 Crossref
15 Scopus

¹Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.

²Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Corresponding author: Bo Kyung Koo. Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 156-707, Korea. bokyungkoomd@gmail.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

Full Article

Download PDF

NOTES
REFERENCES
About this article

Stain is commonly used in subjects with diabetes for both primary and secondary prevention of cardiovascular diseases (CVDs) [1,2]. It is even recommended by the American Diabetes Association to be added to lifestyle therapy regardless of the baseline lipid levels for diabetic patients aged ≥40 years, even if they have no overt CVD [3], and recent guidelines from the American College of Cardiology and the American Heart Association states that statin therapy should be initiated and maintained for the primary prevention for CVD in adults 40 to 75 years of age with diabetes mellitus, regardless of their CVD risk if their low density lipoprotein cholesterol (LDL-C) level is ≥70 mg/dL [4].

The possibility of primary prevention of CVD with statin therapy for diabetic subjects with a high CVD risk has been well elucidated [1,5,6]. Collaborative Atorvastatin Diabetes Study (CARDS) [1] was a large randomized controlled trial aimed to show the efficacy of statin for the primary prevention of CVD in subjects with type 2 diabetes who had at least one or more of CVD risk factors, but the study terminated 2 years earlier than expected. This was because the statin group showed a superior risk reduction than expected: CVD event reduction of 37% (95% confidence interval [CI], -52 to -17) in statin group [1]. However, there are still insufficient evidence to show the effect of statin for the primary prevention of CVD in diabetic patients with a low risk.

There have been claims that statins should be used with caution for the primary prevention in subjects with low CVD risk [7,8]. Furthermore, statin therapy has been reported to be associated with myopathy, elevated liver enzyme concentration, and incident diabetes mellitus [9,10]. However, recent meta-analysis of Cholesterol Treatment Trialists' (CTT) collaborators showed an overall relative risk reduction of major vascular events of 21% (relative risk, 0.79; 95% CI, 0.77 to 0.81) per 1 mmol/L reduction of LDL-C with statin; these benefits were similar in people with a lower CVD risk [11]. Subjects with less than 5% of CVD risk also showed a significant risk reduction of about 40% per 1 mmol/L reduction of LDL-C with statin [11]. In addition, Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) [12] showed that statin decreased the rate of CVD in healthy men and women with LDL-C level ≤130 mg/dL.

Although CTT and JUPITER was not performed exclusively in diabetic patients, their results might be implicated with diabetic subjects with a low CVD risk. Moreover, diabetes is an important risk factor for CVD and is considered as an equivalent to coronary artery disease [13]. Reductions in CVD outcomes were greatest in people with high baseline CVD risk [10]. Nonetheless, subgroup analysis from the meta-analysis of CTT reported that statin could reduce CVD events in subjects with diabetes regardless of their baseline CVD risk or baseline LDL-C [6].

Lee et al. [14] reported that statin discontinuation could be considered based on the pretreatment lipid profiles, especially for subjects with baseline LDL-C less than 123 mg/dL. However, considering that statin therapy is not for reducing LDL-C itself but for reducing CVD risk, their results should be interpreted carefully to make the decision whether statin should be continued or not. As the authors mentioned, the effect of stopping statin on future CVD risk in diabetic patients with a low CVD risk remains to be elucidated.

There have been obvious concerns on the cost-effectiveness of primary prevention of CVD with statin in diabetic subjects with a low CVD risk. CARDS applied the United Kingdom Prospective Diabetes Study risk engine for their study population to predict the probability of a CVD event for each CARDS patient and showed that the incremental cost-effectiveness ratio was £5,983 per event-free year for subjects with a low CVD risk and £2,077 per event-free year for subjects with a high CVD risk [15]. In addition, other issues such as feasibility and desirability should be considered to treat the majority of diabetic patients aged ≥40 years and the role of alternative public health strategies to lower blood cholesterol.

In conclusion, the use of statins for the primary prevention in diabetic subjects with a low CVD risk remains suspensive in its cost-effectiveness. Considering the high risk of CVD in diabetic patients compared to non-diabetic individuals, further studies to elucidate whether statin therapy should be started and maintained for diabetic subjects with a low CVD risk should be performed.

NOTES

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696. Article PubMed
2. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-620. Article PubMed PDF
3. American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care 2014;37(Suppl 1):S14-S80. Article PubMed PDF
4. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith SC Jr, Levy D, Watson K, Wilson PW. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013 11 07 Epub http://dx.doi.org/10.1016/j.jacc.2013.11.002.
5. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016. Article PubMed
6. Cholesterol Treatment Trialists' (CTT) Collaborators. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-125. Article PubMed
7. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010;170:1024-1031. Article PubMed
8. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011;1:CD004816Article
9. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013;346:f2610Article PubMed PMC
10. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816Article
11. Cholesterol Treatment Trialists' (CTT) Collaborators. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-590. Article PubMed PMC
12. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207. Article PubMed
13. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234. Article PubMed
14. Lee SH, Kwon HS, Park YM, Ko SH, Choi YH, Yoon KH, Ahn YB. Statin discontinuation after achieving a target low density lipoprotein cholesterol level in type 2 diabetic patients without cardiovascular disease: a randomized controlled study. Diabetes Metab J 2014;38:64-73.Article PubMed PMC
15. Raikou M, McGuire A, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, Fuller JH. CARDS Investigators. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007;50:733-740. Article PubMed PDF

Figure & Data

References

Citations

Citations to this article as recorded by

Application of PCSK9 Inhibitors in Lipid Metabolism and Arteriosclerosis
扬刘
Advances in Clinical Medicine.2023; 13(08): 12430. CrossRef
Bempedoic acid a novel drug used for the treatment of Hyperlipidaemia: A Review
Rahul D. Shimpi, Shashikant D. Barhate, Mayur S. Jain
Asian Journal of Pharmaceutical Research.2023; : 68. CrossRef
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study
Gyuri Kim, Suk-Yong Jang, Chung Mo Nam, Eun Seok Kang
Journal of Hepatology.2018; 68(3): 476. CrossRef
Change in ALT levels after administration of HMG‐CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice
Hyunah Kim, Hyeseon Lee, Tong Min Kim, So Jung Yang, Seo Yeon Baik, Seung‐Hwan Lee, Jae‐Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, In Young Choi, Kun‐Ho Yoon, Hun‐Sung Kim
Cardiovascular Therapeutics.2018;[Epub] CrossRef
Phenotyping of Korean patients with better-than-expected efficacy of moderate-intensity statins using tensor factorization
Jingyun Choi, Yejin Kim, Hun-Sung Kim, In Young Choi, Hwanjo Yu, Katriina Aalto-Setala
PLOS ONE.2018; 13(6): e0197518. CrossRef
Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
Eugene Han, Gyuri Kim, Ji-Yeon Lee, Yong-ho Lee, Beom Seok Kim, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang
Endocrinology and Metabolism.2017; 32(2): 274. CrossRef
Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case‐control study
Gyuri Kim, Suk‐Yong Jang, Eugene Han, Yong‐ho Lee, Se‐young Park, Chung Mo Nam, Eun Seok Kang
International Journal of Cancer.2017; 140(4): 798. CrossRef
PCSK9 as a therapeutic target for cardiovascular disease
Pei-Ying Zhang
Experimental and Therapeutic Medicine.2017; 13(3): 810. CrossRef
Use of Moderate‐Intensity Statins for Low‐Density Lipoprotein Cholesterol Level above 190 mg/dL at Baseline in Koreans
Hun‐Sung Kim, Hyeseon Lee, Sue Hyun Lee, Yoo Jin Jeong, Tong Min Kim, So Jung Yang, Sun Jung Baik, Hyunah Kim, Seung‐Hwan Lee, Jae Hyoung Cho, In‐Young Choi, Kun‐Ho Yoon, Ju Han Kim
Basic & Clinical Pharmacology & Toxicology.2017; 121(4): 272. CrossRef
Cellular Model of Atherogenesis Based on Pluripotent Vascular Wall Pericytes
Ekaterina A. Ivanova, Alexander N. Orekhov, Agnes L. Nishimura
Stem Cells International.2016;[Epub] CrossRef
PCSK9 inhibitors in the prevention of cardiovascular disease
James Latimer, Jonathan A. Batty, R. Dermot G. Neely, Vijay Kunadian
Journal of Thrombosis and Thrombolysis.2016; 42(3): 405. CrossRef
Analysis and comparison of statin prescription patterns and outcomes according to clinical department
H.-S. Kim, H. Kim, H. Lee, B. Park, S. Park, S.-H. Lee, J. H. Cho, H. Song, J. H. Kim, K.-H. Yoon, I. Y. Choi
Journal of Clinical Pharmacy and Therapeutics.2016; 41(1): 70. CrossRef
Statin‐related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea
H.‐S. Kim, S. H. Lee, H. Kim, S.‐H. Lee, J. H. Cho, H. Lee, H. W. Yim, S.‐H. Kim, I.‐Y. Choi, K.‐H. Yoon, J. H. Kim
Journal of Clinical Pharmacy and Therapeutics.2016; 41(3): 266. CrossRef
New Drugs for Treating Dyslipidemia: Beyond Statins
Chang Ho Ahn, Sung Hee Choi
Diabetes & Metabolism Journal.2015; 39(2): 87. CrossRef
Pharmacological treatment and therapeutic perspectives of metabolic syndrome
Soo Lim, Robert H. Eckel
Reviews in Endocrine and Metabolic Disorders.2014; 15(4): 329. CrossRef

PubReader

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Statin for the Primary Prevention of Cardiovascular Disease in Patients with Diabetes Mellitus

Diabetes Metab J. 2014;38(1):32-34. Published online February 19, 2014

DOI: https://doi.org/10.4093/dmj.2014.38.1.32

XML Download

Related articles

Statin for the Primary Prevention of Cardiovascular Disease in Patients with Diabetes Mellitus

About this article

Koo BK. Statin for the Primary Prevention of Cardiovascular Disease in Patients with Diabetes Mellitus. Diabetes Metab J. 2014;38(1):32-34.

DOI: https://doi.org/10.4093/dmj.2014.38.1.32.

Download citation ↓